Bought some of these this morning as Instiutional interest as really boiled up over them. They have just announced a very positive deal and from what I can see theres quite a lot of news flow in the pipeline to keep this one going throughout the rest of the year. Its highly speculative but give me a Bio company that isnt.

Heres just a little historical detail about the company from the last results prelims 31/12/2004.

HIGHLIGHTS

Listing on London Stock Exchange raised 55 million
Kerraboot(R) received UK Drug Tariff Listing at a reimbursement price
of 14
Kerraboot(R) UK sales showed steady upward trend in first six months
of primary care promotion
Second safety and efficacy study for Cerepro(TM) showed mean patient
survival time increased by 80% in malignant glioma
Trinam(R) received Orphan Drug Designation in the EU
First international out-licensing deal signed with Teva Medical for
Kerraboot(R) in Israel
EG005 Phase II in lipodystrophy completed enrolment
Finnish manufacturing facility received Good Manufacturing Practice
certification (cGMP)
Named patient supplies of Vitor(TM) made available at request of
investigators for patients completing Phase III study
Cash of 47 million at 31 December 2004

POST YEAR-END EVENTS

Patent for Trinam(R) granted by European Patent Office

Dr Nigel Parker, CEO of Ark, commented:

'We made substantial progress in all aspects of our business in 2004 and
demonstrated that we are delivering on key milestones during our first year as a
publicly quoted company. Our progress to date supports our belief that we are
well placed to achieve our goal of becoming one of a successful new breed of
diversified healthcare companies servicing areas of high clinical need in
hospital and specialist medicine.'

ARKs History

Ark Therapeutics Group plc

Ark is a specialist healthcare group (the 'Group') with one marketed product and
three further lead products in late stage clinical development. Capitalising on
over ten years of research in vascular biology and gene-based medicine, Ark has
a balanced product portfolio targeted at specific unmet clinical needs within
vascular disease and cancer. These are large and growing markets, where
opportunities exist for effective new products to generate significant revenues.

Ark's products are sourced from related but largely non-dependent technologies
within the Group and have been selected to enable them to be taken through
development within the Company's own means and to benefit from Orphan Drug
Status and/or Fast Track Designation, as appropriate. This strategy has allowed
the Group to retain greater value and greater control of clinical development
timelines, and to mitigate the risks of dependency on any one particular
programme or development partner. Ark has secured patents or has patent
applications pending for all its lead products in principal pharmaceutical
markets.

Ark has its origins in businesses established in the mid-1990s by Professor John
Martin and Mr Stephen Barker of University College London and Professor Seppo
Yla-Herttuala of the AI Virtanen Institute at the University of Kuopio,
Finland, all of whom continue to play leading roles in the Company's research
and development programmes.

You can find full details of the last results here, http://www.uk-wire.com/cgi-bin/articles/200503100700205623J.html

Worth a punt I feel but as I have previously stated its high risk.

DYOR.

cheers GF.

Ark Therapeutics Group PLC
05 October 2005

Ark completes development of oxLDL diagnostic kit for prediction of heart attack
risk

Product now CE-marked in preparation for commercialisation


London, UK, 5 October 2005: Ark Therapeutics Group plc ('Ark'), today announces
that it has completed the development and European CE marking of its oxidised
low density lipoprotein antibody testing kit, oxLDL. The diagnostic kit will be
used to predict whether an individual is at risk of having a heart attack.

Patients with cardiovascular disease exhibit a build up of fats and abnormal
tissue, known as atherosclerotic plaques, on the inside of their blood vessels.
Whilst plaques can lay dormant with minimal risk to the patient, they can become
active and unstable, eventually rupturing and releasing fragments of plaque into
the bloodstream. This 'breakaway' plaque is circulated by the blood and can
lodge in the coronary artery causing a heart attack, or in the blood vessels
supplying the brain causing a stroke.

As plaque becomes active, it releases a specific chemical, an oxidised form of
low density lipoprotein (oxLDL), into the blood stream in amounts that reflect
the level of the plaque's instability. As such, oxLDL has become increasingly
recognised as a key marker of heart attack risk(1), as the higher its level in
the blood, the more likelihood there is of the plaque breaking away and causing
a serious cardiovascular event.

Attempts to produce a reliable and easy to use test to measure oxLDL have not
been successful to date, as the oxLDL molecule only exists for a very short time
in the blood. However, as oxLDL is released into the blood, it rapidly produces
an antibody response. Ark's test, the first of its kind, is a highly sensitive
measure of the level of antibodies that are produced in response to oxLDL. The
test also contains a control chemical to check whether a positive result is real
or false.

Clinical results to date using Ark's test have shown that the test is applicable
to approximately 75% of people and is highly predictive. In a study of patients
with chest pain entering hospital for investigation, 81% of the patients who
tested positive using Ark's kit were subsequently confirmed as having a serious
cardiovascular problem (heart attack or unstable angina). The test was even
more accurate where heart attack occurred. C-reactive protein (CRP), one of the
current 'gold standards' in predicting risk of cardiovascular problems, was
predictive in only 29% of the cases in the same study.

Professor John Martin, Chair of Cardiovascular Medicine at University College
London and Chief Scientific Officer at Ark, commented: 'This new diagnostic is
highly predictive and has the potential to save many lives. It should prove a
very useful addition to the overall cardiovascular risk testing approach.'

Dr Nigel Parker, Chief Executive of Ark, added: 'This is the second product that
Ark has taken all the way through the development process to CE marking. We
shall now be seeking specialist diagnostic partners to help us market the
product and ensure that it realises its full commercial potential.'

Cheers, Madison

Excellent news, thanks Madison!

And more again:

Ark Therapeutics Group PLC
20 October 2005


Ark receives licence to manufacture first gene medicine for commercial supply


London, UK, 20 October 2005: Ark Therapeutics Group plc ('Ark') announces today
that, following an inspection by the Finnish National Agency for Medicines, on
behalf of the European Medicines Agency (EMEA), its facility in Kuopio, Finland
has received Good Manufacturing Practice (GMP) Certification to manufacture
commercial supplies of its adenoviral-based gene medicine CereproTM, a gene
based medicine for the treatment of brain cancer.

Ark's facility, in Kuopio, Finland is believed to be the only facility outside
of China to have been licensed to manufacture gene based medicines for
commercial supply.

Nigel Parker, CEO of Ark, commented: 'This is a tremendous achievement by the
Company. A number of years of meticulous planning and work have gone into
achieving this certification and it endorses our leadership position in this
upcoming area of molecular medicine.'

Cheers, Madison

Again, great news Madison. Is momentum building now for a push higher?

And more good news:

Ark Therapeutics gets 2.19 mln eur grant for new Finnish manufacturing facility
AFX


LONDON (AFX) - Ark Therapeutics Group PLC said it has received a 2.19 mln eur grant from the Employment and Economic Development Centre of Finland for its new GMP manufacturing facility.

The facility is currently being prepared for commercial-scale manufacture of Cerepro, a gene-based medicine for the treatment of brain cancer. The new facility will significantly increase Ark's manufacturing capacity and scope in the gene-based medicines.

Work on the facility has already commenced and Ark Therapeutics expects it to be operational for validation to commence towards the end of 2007.

newsdesk@afxnews.com

Cheers, Madison

Splendid news Madison. The sp needs a bit of a push. Let's hope this does it!

I assume the rise which started on Friday 11/11 results from Nomura reiterating "strong buy" but changing price target from 249 to 349. Seems a bit fantastical to me, but I'm not complaining about this rise!

Cheers, Madison

349? Slowly but surely!

BrainsTrust Market Report: Fair wind pushes Ark up the league

Published: 15:10 Wednesday 16 November 2005
By: Cliff Feltham, Companies Correspondent

Strong demand for healthcare group Ark Therapeutics pushed the shares up nearly 12% last week and into 20th place in the Citywire BrainsTrust SmallCap index.

The group (AKT) is engaged in research into a number of gene-based medicines and a surfeit of encouraging news during October fuelled the rise, which has left the shares 44% up on the year. Broker Nomura says the company is on track to deliver three innovative drugs and has lifted its valuation of the shares to 358p against 114p today.

Cheers, Madison

Thanks Madison - still very encouraging.

Is anyone else still in these (GF?)....

SP doing very well lately.

Surely this last batch of large trades showing as sells cannot all be really sells or sp would have plummetted? I have been watching this stock for a long time, and it seems to me that the classification of buys and sells is particularly unlikely. Anyone else have this suspicion, or is it just my imagination?

Cheers, Madison

Not sure Madison. Down again today though but still feels strong.....

Ark Therapeutics Group PLC
12 January 2006




Ark Receives US Patent for Kerraboot(R)



12 January 2006, London UK: Ark Therapeutics Group plc today announces the grant
of its patent in the US, Patent Number 6982358, for Kerraboot(R), a novel
woundcare device for the management of leg and foot ulcers. Kerraboot(R) has
already been listed for marketing by the Food and Drug Administration in the US.



Kerraboot(R) is currently marketed by Ark in the UK with increasing clinical
success reported amongst nursing and hospital communities. Late last year Ark
launched a new and more versatile extra-absorbent version of the device to
extend both the range of ulcers that can be treated and the length of treatment
for more exudative wounds. Launched in response to market demand, the new
version has had a very favourable reception from nurses and other healthcare
providers. The Company also intends to release an opaque version in early 2006
for those patients who do not want their wounds to be visible. The Company has
signed distribution agreements for Israel, Ireland and South Korea, and further
such agreements and the commencement of international sales are expected during
2006.



Lower leg and foot ulceration affects around 1% of the adult population in the
developed world1 and is particularly prevalent amongst the diabetic population,
in which the ulcers can develop rapidly, are particularly difficult to heal and
can sometimes lead to amputation.



Kerraboot(R) provides a new approach to the management of these ulcers, in the
form of a novel, non-pressurised, boot-like dressing device, which is simple,
quick and less painful to change. Kerraboot(R) facilitates the draining and
isolation of exudates such as matrix metalloproteases, which inhibit
angiogenesis, from the ulcer. This allows natural growth factors such as
Vascular Endothelial Growth Factors (VEGF) to stimulate healing. In clinical
studies of ulcers managed with Kerraboot(R), reductions in ulcer sizes of up to
60% have been observed over the four-week study period, with both healthcare
professionals and patients expressing a strong preference for Kerraboot(R) over
current standard treatments. UK based studies have also shown that management of
ulcers with Kerraboot(R), which does not involve any additional dressings, can
be extremely cost effective.



Nigel Parker, Chief Executive of Ark, commented: 'The US patent has been a while
coming and its grant will now enable us to progress our commercialisation
strategy for Kerraboot(R) in the US market. We are increasingly encouraged by
the number of independent case reports being published demonstrating the
effectiveness of Kerraboot(R) and by the response to the new version. We are
also now seeing Kerraboot(R) being taken up by increasing numbers of primary
care trust formularies in the UK. We believe that there is a significant
opportunity for Kerraboot(R) in the US market and we look forward to updating
shareholders regarding our UK and international progress in the coming months.'

Excellent news Madison, thanks.

Excellent news - and the sp down. Why???????????????/

15 February 2006, London UK: Ark Therapeutics Group plc today announces that it
has signed an exclusive licensing agreement granting Sino Tau International
Company Limited (Sino Tau), a Chinese healthcare company, the sales and
marketing rights to Kerraboot(R) for the Chinese market. Kerraboot(R) is Ark's
novel wound care device for the management of leg and foot ulcers. Sino Tau,
based in Beijing, is an established distributor of both pharmaceuticals and
medical devices in China and markets products through its own sales and
sub-distributor network.

Under the terms of the licence, Sino Tau will be responsible for all the
processes necessary to market Kerraboot(R), including obtaining the necessary
Government and regional approvals. Ark will supply the product to Sino Tau at
an agreed transfer price. Other financial terms of the transaction were not
disclosed.

China has a population of 1.3 billion and lower leg and foot ulceration affects
around 2% of the adult population. At present, approximately 40% of the Chinese
population is able to afford western healthcare products and these people are
located in the main urban areas. The market potential for Kerraboot(R) in
China is very large and it will initially be marketed for the growing problem of
diabetic ulcers and those venous ulcer patients who are intolerant of current
treatments, giving an estimated initial target group of 160,000 patients(1). The
prevalence of diabetes in China is approximately three times higher than 10
years ago and China now ranks second, behind India, as the country with the
highest prevalence, with an estimated 24 million diabetic population1.
Diabetics are 25 times more likely to lose a leg by amputation than non
diabetics and it is estimated that 50,000 diabetes-related lower extremity
amputations are performed each year in China, of which 85% are preceded by a
foot ulcer(2).

Kerraboot(R) provides a new approach to the management of these ulcers, in the
form of a novel, non pressurized, boot-like dressing device, which is simple,
quick and pain free to change. Kerraboot(R) facilitates the draining and
isolation of wound exudates such as matrix metalloproteases (which inhibit
angiogenesis) from the ulcer. This allows natural growth factors, such as
Vascular Endothelial Growth Factors (VEGF), to stimulate healing. In clinical
studies of ulcers managed with Kerraboot(R), reductions in ulcer sizes of up to
60% were observed over the four-week study period, with both healthcare
professionals and patients expressing a strong preference for Kerraboot(R) over
current standard treatments. UK-based studies have also shown that management of
ulcers with Kerraboot(R), which does not involve any additional dressings, can
be extremely cost effective saving up to 50% of nurse time and with patients
often becoming nurse independent. Late last year Ark launched a new and more
versatile extra-absorbent version of the device to extend both the range of
ulcers that can be treated and the length of treatment for more exudative
wounds. Launched in response to market demand, the new version has had a very
favourable reception from nurses and other healthcare professionals. Ark will
be supplying the extra absorbent version to its international licensees.

Nigel Parker, CEO of Ark, commented: 'The flow of independent case histories
illustrating the effectiveness of Kerraboot(R) in managing leg ulcers has been
of increasing interest to potential partners. This licensing deal with Sino Tau
opens up a very substantial market in which Kerraboot(R) can make a significant
impact on those suffering from these serious conditions. We continue to discuss
licensing arrangements with other international partners to bring the benefits
of Kerraboot(R) to the greatest possible number of patients.'

Bought in first thing on this news and promptly sold out again as I am worried about the reaction.

One problem I have with the announcement is that they do not mention financials, which is unusual for bios as they like chucking numbers around.

I will wait to see if there is anything further brought to light in the press.

Interesting news re the placing today. Seems there's a lot of interest.

So what's new with AKT? Nice little rises the previous two sessions and a good rise so far today. News around the corner?

I bought shares in AKT on Tuesday 29th of this month.

I thought it strange that it never showed. Not the norm is it.

So this is why we've had the nice rises these past few days:

Ark Therapeutics said it observed improvements in metabolic risk factors in initial results from the open label one year extension phase of its exploratory phase II study of EG005 for the treatment of lipodystrophy -- the accumlation of central body fat -- in HIV positive patients. The company said the patient group completing the extension phase showed 'little or no deterioration from baseline in mean scores for the main disease markers of central and peripheral fat and total body fat measurements nor in the waist, trunk, hip and thigh measurements'.

However, individual patients showed considerable variation from baseline by the end of the treatment period, although mean scores for the main body shape measurements indicated that the group overall had not deteriorated significantly whilst on treatment. In addition the overall group showed no deterioration in mean lean body mass score during the study.

John Martin, CSO said: 'This initial study seems to support the hypothesis that EG005 has a beneficial metabolic effect and specifically on the cardiovascular and diabetic consequences of the disease. It would suggest further exploratory work is needed to investigate these effects before determining how to take the product into full development.'